Seq,DocuTitle,Country,TestPeriod,TestTareget,Antibody_Sample,Origin
1,Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020,호주/시드니,2020년 4-6월,잔여 혈액 샘플: 1. 혈액 병리검사 (19/3231) 모든 연령대 2. 산전 선별검사 (7/560) 20-39세 3. 플라즈마페레제 기증 (12/1548) 20-69세,1. 0.15% (general pathology) 2. 0.79% (Antenatal screening) 3. 0.29% (Plasmapheresis donors),"Gidding HF, Machalek DA, Hendry AJ, et al. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020. Med J Aust. 2021;214(4):179-185. doi:10.5694/mja2.50940"
2,A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting,호주,2020년 6-7월,대기 수술 환자 (41/2991),0.0028,"Hicks SM, Pohl K, Neeman T, et al. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. J Infect Dis. 2021;223(1):10-14. doi:10.1093/infdis/jiaa623"
3,Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown,오스트리아/비엔나,"2020년 4-5월 ","일반 인구+LEAD 코호트 구성원 (163/12419) ",0.0113,"Breyer MK, Breyer-Kohansal R, Hartl S, et al. Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown. Sci Rep. 2021;11(1):10158. Published 2021 May 12. doi:10.1038/s41598-021-89711-5"
4,Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe,오스트리아,"2020년 7월 ",건강보험 가입자 [의료진 (23/2242) 비의료진 (65/5301)],"1% (의료진), 1.2% (비의료진) ","Bartko J, Zehetmayer S, Weseslindtner L, et al. Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe. J Clin Med. 2021;10(9):1909. Published 2021 Apr 28. doi:10.3390/jcm10091909"
5,Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium ? a serial prospective cross-sectional nationwide study of residual samples,벨기에,"2020년 3-7월 ","잔여 혈액 샘플 (3000-4000)                ","5기간으로 구분                                           1. 2.9%, 2. 6%, 3. 6.9%, 4. 5.5%, 5. 4.5%","Herzog SDB; Abrams, S; Wouters, I; Ekinci, E; Patteet, L; Coppens, A; et al: Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium – a serial prospective cross-sectional nationwide study of residual samples. 2020. doi:10.1101/2020.06.08.20125179"
6,Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff,벨기에/브뤼셀,2020년 4-5월,병원 의료진 36/326,0.11,"Martin C, Montesinos I, Dauby N, et al. Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff. J Hosp Infect. 2020;106(1):102-106. doi:10.1016/j.jhin.2020.06.028"
7,SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada,캐나다,"2020년 5-7월 ","혈액기증자 552/74642 ",0.007,"Saeed S, Drews SJ, Pambrun C, Yi QL, Osmond L, O'Brien SF. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada. Transfusion. 2021 Mar;61(3):862-872. doi: 10.1111/trf.16296"
8,"SARS-CoV-2 seroprevalence among blood donors in Quebec, and analysis of symptoms associated with seropositivity: a nested case-control study",캐나다/퀘벡,"2020년 5-7월 ",잔여 혈액 샘플 (혈액기증자) 173/7691,0.0225,"Lewin A, Therrien R, De Serres G, et al. SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study [published online ahead of print, 2021 May 17]. Can J Public Health. 2021;1-11. doi:10.17269/s41997-021-00531-6"
9,"Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020",캐나다/브리티시컬럼비아,"2020년 3-5월 ","잔여 혈액 샘플  (3월-2/869), (5월-4/885)",3월-0.28% 5월-0.55%,"Skowronski DM, Sekirov I, Sabaiduc S, et al. Low SARS‐CoV‐2 sero‐prevalence based on anonymized residual sero‐survey before and after first wave measures in British Columbia, Canada, march‐may 2020. medRxiv. 2020. doi:10.1101/2020.07.13.20153148"
10,Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile,칠레,"2020년 4-7월 ",의료진 107/446,overall seroprevalence 24%,"Iruretagoyena M, Vial MR, Spencer-Sandino M, et al. Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile. BMC Infect Dis. 2021;21(1):478. Published 2021 May 26. doi:10.1186/s12879-021-06208-2"
11,SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study,칠레,2020년 5월,"학생 100/1009, 교직원 39/235","overall seroprevalence 9.9% (학생), 16.6% (교직원) ","Torres JP, Piñera C, De La Maza V,et al. SARS-CoV-2 antibody prevalence in blood in a large school community subject to a Covid-19 outbreak: a cross-sectional study. Clin Infect Dis. 2020 Jul 10:ciaa955. doi: 10.1093/cid/ciaa955."
12,Searching for COVID-19 Antibodies in Czech Children?A Needle in the Haystack,체코,2020년 7-8월,소아과 병원 0/200,>0.5%,"Bloomfield M, Pospisilova I, Cabelova T, Sediva A, Ibrahimova M, Borecka K, Magner M. Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack. Front Pediatr. 2020 Nov 12;8:597736. doi: 10.3389/fped.2020.597736."
13,Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors,덴마크,2020년 4-5월,혈액 기증자 412/20640,0.019,"Erikstrup C, Hother CE, Pedersen OBV, et al. Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors. Clin Infect Dis. 2021;72(2):249-253. doi:10.1093/cid/ciaa849"
14,Risk of COVID-19 in health-care workers in Denmark: an observational cohort study,덴마크,2020년 4월,의료진 1. IgG (808/28792) 2. IgM (768/28792) 3. IgG or IgM (1163/28792) 혈액 기증 1. IgG (86/4672) 2. IgM (92/4672) 3. IgG or IgM (142/4672),의료진 1. IgG (2.81%) 2. IgM (1.43%) 3. IgG or IgM (4.04%) 혈액 기증 1. IgG (1.97%) 2. IgM (1.84%) 3. IgG or IgM (3.04%),"Iversen K, Bundgaard H, Hasselbalch RB, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study [published correction appears in Lancet Infect Dis. 2020 Oct;20(10):e250]. Lancet Infect Dis. 2020;20(12):1401-1408. doi:10.1016/S1473-3099(20)30589-2"
15,Seroprevalence of SARS-CoV-2 IgG antibodies in two regions of Estonia (KoroSero-EST-1),"에스토니아/탈린, 사레마","2020년 5-7월 ",의료진 73/1960,"1.5 % 탈린, 6.3% 사레마","Jogi P, Soeorg H, Ingerainen D, Soots M, et al. Seroprevalence of SARS-CoV-2 IgG antibodies in two regions of Estonia (KoroSero-EST-1). medRxiv. 2020 Jan 1. doi:10.1101/2020.10.21.20216820"
16,Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors,핀란드,"2020년 4-5월 ",혈액 기증자 412/20640,0.019,"Erikstrup C, Hother CE, Pedersen OBV, et al. . Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors. Clin Infect Dis 2020 doi:10.1093/cid/ciaa849"
17,Cluster of COVID-19 in Northern France: A Retrospective Closed Cohort Study,프랑스,"2020년 3-4월 ","학생, 교직원,학부모 171/661 ",0.03,"Fontanet A, Tondeur L, Madec Y, et al. . Cluster of COVID-19 in northern France: a retrospective closed cohort study. SSRN Journal 2020. DOI:10.2139/ssrn.3582749"
18,Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance,프랑스,"2020년 3-5월 ","전국 잔여 혈액 샘플 1. 3월 (1/3221) 2. 4월 (66/3084) 3. 5월 (87/2879) ","3월 0.41%, 4월 4.14%, 5월  4.93%","Le Vu S, Jones G, Anna F, et al. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. Nat Commun. 2021;12(1):3025. Published 2021 May 21. doi:10.1038/s41467-021-23233-6"
19,"Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn, Germany",독일/본,"2020년 4-6월 ",Rhineland 코호트 구성원 46/4771,0.0097," Aziz NA, Corman VM, Antje KC. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: results from a population-based study in Bonn, Germany. MedRxiv 2020. doi:10.1101/2020.08.24.20181206"
20,Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study,독일,"2020년 3-7월 ",의료센터 직원 22/1253,0.018,"Brehm TT, Schwinge D, Lampalzer S, et al. Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study. Int J Hyg Environ Health. 2021;232:113671. doi:10.1016/j.ijheh.2020.113671"
21,"SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020",독일,"2020년 3-6월 ",혈액 기증자 1. North Rhine-Westphalia 16/1700 2. Lower Saxony 7/576 3. Hesse 6/910,0.91% (0.58–1.24) 1. North Rhine-Westphalia 0.94%  2. Lower Saxony 1.22% 3. Hesse 0.66%,"Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill. 2020;25(28):2001285. doi:10.2807/1560-7917.ES.2020.25.28.2001285"
22,"Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020",그리스,"2020년 3-4월 ",일반 인구 집단 잔여 혈액 24/6586,"3월 0.02%, 4월 0.25%","Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Euro Surveill. 2020;25(31):2001369. doi:10.2807/1560-7917.ES.2020.25.31.2001369"
23,"Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020",그리스,"2020년 5-8월 ",일반 인구 집단 잔여 혈액 89/20110,"5월 0.35%, 6월 0.19%, 7월 0.25%, 8월 0.35%","Bogogiannidou Z, Speletas M, Vontas A, et al. Repeated Leftover Serosurvey of SARS-CoV-2 IgG Antibodies in Greece, May to August 2020. Vaccines (Basel). 2021;9(5):504. Published 2021 May 13. doi:10.3390/vaccines9050504"
24,Seroprevalence study of SARS-CoV-2 infection in General Practice in Ireland,아일랜드,"2020년 6-7월 ",병원 환자/직원,"12.6% 환자, 11.1% 직원","O'Callaghan ME, Ryan E, Walsh C, et al. Seroprevalence study of SARS-CoV-2 infection in General Practice in Ireland. BJGP open. 2021 May 18. doi:10.3399/BJGPO.2021.0038"
25,Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel,이스라엘,"2020년 4월 ",류머티즘 환자 5/242,0.0207,"Eviatar T, Elalouf O, Furer V, et al. Prevalence of COVID‐19 and seroprevalence to SARS‐CoV‐2 in a rheumatologic patient population from a tertiary referral clinic in Israel. Internal Medicine Journal. 2021 May;51(5):682-690. doi:10.1111/imj.15202"
26,SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan,이탈리아,"2020년 2-4월 ",혈액 기증자 32/120,"2.7% 첫째주, 5.2% 마지막 3주","Valenti L, Bergna A, Pelusi S, et al. SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan. Blood Transfus. 2021;19(3):181-189. doi:10.2450/2021.0324-20"
27,Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan,일본/도쿄,"2020년 8-10월 ",암센터 1. 의료진 8/1190 2. 환자 5/500,"의료진 0.67%, 환자 1%","Yazaki S, Yoshida T, Kojima Y, et al. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan. JAMA oncology. 2021 May 28. e212159 doi:10.1001/jamaoncol.2021.2159"
28,Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study.,룩셈부르크,"2020년 4-5월 ",일반 인구 집단 35/1862,0.0197,"Snoeck CJ, Vaillant M, Abdelrahman T. Prevalence of SARS-CoV-2 infection in the Luxembourgish population: the CON-VINCE study. MedRxiv 2020. doi:10.1101/2020.05.11.20092916"
29,SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020,멕시코,"2020년 2-9월; 10-12월 ",전국 잔여 혈액 샘플 4488/24273,"3.5% 2월, 33.5% 12월 ","Muñoz-Medina JE, Grajales-Muñiz C, Salas-Lais AG, et al. SARS-CoV-2 IgG Antibodies Seroprevalence and Sera Neutralizing Activity in MEXICO: A National Cross-Sectional Study during 2020. Microorganisms. 2021;9(4):850. Published 2021 Apr 15. doi:10.3390/microorganisms9040850"
30,"Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study",스페인,2020년 4-5월,전국민 대상 혈액 샘플 51958,0.046,"Pollán M, Pérez-Gómez B, Pastor-Barriuso R, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-544. doi:10.1016/S0140-6736(20)31483-5"
31,"Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study",스위스,2020년 4-5월,SEROCoV-POP 표본 219/2766,"첫쨰주 4.8%, 2주 8.5%, 3주 10.9%, 4주 6.6%, 5주 10.8%","Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-319. doi:10.1016/S0140-6736(20)31304-0"
32,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,영국,"2020년 4-6월 ",TwinsUK 코호트 51/431,0.12,"Wells PM, Doores KJ, Couvreur S, et al. Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England. J Infect. 2020;81(6):931-936. doi:10.1016/j.jinf.2020.10.011"
33,"Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020",미국,"2020년 6-8월 ",혈액 기증자 17336/953926,0.0182,"Dodd RY, Xu M, Stramer SL. Change in Donor Characteristics and Antibodies to SARS-CoV-2 in Donated Blood in the US, June-August 2020. JAMA. 2020;324(16):1677-1679. doi:10.1001/jama.2020.18598"
34,Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area,미국/뉴욕,"2020년 4-6월 ",의료진 5523/40329,0.137,"Moscola J, Sembajwe G, Jarrett M, et al. Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area [published correction appears in JAMA. 2020 Dec 8;324(22):2328] [published correction appears in JAMA. 2020 Dec 8;324(22):2328]. JAMA. 2020;324(9):893-895. doi:10.1001/jama.2020.14765"
35,"Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020",미국/LA,"2020년 4월 ",LA 주민 35/863,0.0406,"Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. JAMA. 2020;323(23):2425-2427. doi:10.1001/jama.2020.8279"
